ProAct, Inc.

ProAct, Inc. is a full-service Pharmacy Benefit Management Company. We do not sell "off-the-shelf" prescription drug plans.

is a full-service Pharmacy Benefit Management Company combining industry-leading client service with the latest in PBM technology to produce innovative, affordable and flexible prescription drug benefit solutions. Our solutions are custom tailored to meet the particular contractual, financial and quality of care needs of each client. Our client base, consisting of manufacturers, universities, muni

cipalities, hospitals, corporations, not-for-profit organizations, long-term care facilities and financial institutions, represents more than two million total lives. Our unique solutions provide cost-effective prescription drug benefits that align with union contract requirements.

07/24/2025

We celebrated the Power of Partnership at the 2025 ProAct Summit! 💥

At ProAct, we believe that our partners keep us at the forefront of growth and innovation, contributing to our ability to deliver robust solutions, manage drug spend, and provide the personalized, high-touch services that are the cornerstone of our approach. Take a look at what our partners had to say about ProAct at this year's annual Summit!

07/21/2025

Mercer, a consulting firm, recently published the results of their new survey. Employers with at least 500 employees were surveyed and according to the results, 51% said they plan to increase cost-sharing in 2026, including raising deductibles and maximum out-of-pocket costs for workers. That percentage increased from 45% in 2025. 77% of employers named the cost of GLP-1 weight loss drugs as their top concern. According to the survey, employers are seeking out alternatives to the traditional, large pharmacy benefit managers (PBMs). Regulatory pressure and calls for transparency are generating interest in new models and smaller mid-market PBMs that offer flexibility, transparency, and innovative approaches to managing drug spend.

Contact ProAct today to learn how we can support the needs of employer groups looking for greater transparency, more control, and flexibility in coverage options.

https://hubs.li/Q03xQFP10

07/14/2025

One week from today, ProAct's very own Suzi Huffman and Marissa Kaplan will be making connections and striking up conversations in Dallas for the HCAA TPA Summit. 🔗 Will they see you there?!

Make sure to keep an eye out for Suzi & Marissa to learn about ProAct's game-changing approach to Pharmacy Benefit Management! 💊

07/08/2025

Meet Jennifer!

07/03/2025

On June 18, 2025, the FDA approved Gilead’s Yeztugo (lenacapavir) for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired human immunodeficiency virus type 1 (HIV-1). Yeztugo is the first FDA-approved, twice-yearly, subcutaneous PrEP option for HIV prevention. Gilead has announced that the list price for Yeztugo will be $28,218 annually.

The U.S. Preventive Services Task Force (USPSTF) has not yet provided a formal recommendation specific to Yeztugo related to coverage under the Affordable Care Act (ACA). However, USPSTF does list their recommendations for PrEP as an “A” grade, which means the Task Force strongly recommends the specific preventive service be covered by insurers and employers. Step therapy restrictions are not permitted for PrEP products under most commercial insurance plans, consistent with Affordable Care Act (ACA) mandates and recommendations from the U.S. Preventive Services Task Force (USPSTF).

https://hubs.li/Q03vpTS90

06/27/2025

📢 We're proud to announce our newest partnership with IMA Financial Group, Inc. As employee-owned companies, we are empowered in providing customized, flexible solutions to our customers.

06/26/2025

The glucagon-like peptide-1 (GLP-1) drug class is expected to continue to expand in both the indications the class treats as well as the number of GLP-1 medications brought to market.

Several GLP-1 medications could receive FDA approval to expand the indications they are approved for by the end of 2025, this includes:
💉Ozempic®: Peripheral artery disease with type 2 diabetes
💉Rybelsus®: Major adverse cardiovascular event (MACE) reduction with type 2 diabetes
💉Wegovy®: Heart failure in obesity and for metabolic dysfunction-associated steatohepatitis (MASH)
💉Oral semaglutide currently sold under the trade name Rybelsus® is pending approval for chronic weight management

In 2026, there will likely be an approval for:
✔️High-dose versions of Rybelsus® and Wegovy®
✔️Expanded indication for Mounjaro® for MACE reduction in type 2 diabetes
✔️A new oral GLP-1, Eli Lilly’s orforglipron, approved for both obesity and type 2 diabetes
✔️Semaglutide in the treatment of Alzheimer’s disease

As GLP-1 treatments gain additional indications and new drugs come to market, it's important to have a comprehensive pharmacy benefit management approach in managing utilization. Please contact your ProAct account manager or a member of our dedicated sales team for more information! Click here: https://hubs.li/Q03tkyy-0

https://hubs.li/Q03tks6W0

06/24/2025

ProAct's very own Suzi Huffman, MHA and RJ Smith will be heading to the sunshine state for the NABIP Annual Convention in Miami! ☀️ Will they see you out and about this weekend?

Make sure to keep an eye out for Suzi & RJ to learn about ProAct's game-changing approach to Pharmacy Benefit Management! 💊

06/17/2025

Last week's annual ProAct Summit was unforgettable! What an incredible three days – from Crystal Washington's keynote to inspiring presentations and meaningful partner connections – the energy was undeniable. 💥

Thank you to our partners who keep ProAct at the forefront of growth and innovation, allowing us to deliver high-touch pharmacy benefit management services. If you weren't able to attend this year's ProAct Summit, we look forward to connecting with you at the next one!

06/12/2025

ProAct employee owners laced up their sneakers and joined forces with our sister company Noble Health Services for the Syracuse Workforce Run. 🏃👟 It was a night filled with comradery, fun, and great conversations!

The money raised from the 2025 Syracuse Workforce Run benefits the Ronald McDonald House of Central New York, a nonprofit organization that helps families with critically ill children receive comfort and support throughout their healthcare journey.

06/09/2025

Recently, two studies published in the Journal of The American Medical Association investigated the return on investment associated with coverage of GLP-1 agonists in the treatment of obesity. The study titled “Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity” evaluated what the 10-year fiscal impact on Medicare Part D would be if they were to cover GLP-1 agonists for obesity. Among 30 million cumulative Medicare beneficiaries, the analysis estimated that 3 million would receive treatment. Medicare’s total drug costs were projected at $65.9 billion and health care cost offsets from clinical benefits at $18.2 billion, resulting in net increased spending of $47.7 billion. However, these savings were estimated to remain less than additional spending on GLP-1 agonists and to extensively increase net spending. The study titled “Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults” evaluated 4 anti-obesity medications, tirzepatide and semaglutide were found to generate greater lifetime health gains by preventing diabetes, cardiovascular complications, and death compared to phentermine-topiramate and naltrexone-bupropion; however, they are not cost-effective at their current net prices.

https://hubs.li/Q03rf9c90
https://hubs.li/Q03rf9fY0

06/06/2025

We broke down the biggest drug trend shifts – so you don't have to. 📈

The world of pharmacy benefits is complex, that's why ProAct develops a long-term, high-touch relationship with plan sponsors to alleviate the complexity of the changing prescription benefits environment.

Request ProAct's 2025 Drug Trend Report and Drug Pipeline Report to learn why ProAct consistently outperforms in the PBM landscape. Click here today: https://hubs.li/Q03r20tr0

Address

East Syracuse, NY

Telephone

+18662879885

Website

https://www.proactrx.com/

Alerts

Be the first to know and let us send you an email when ProAct, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ProAct, Inc.: